83 related articles for article (PubMed ID: 19419311)
1. CXCL12/CXCR4 axis in tissue targeting and bone destruction in cancer and multiple myeloma.
Ooi LL; Dunstan CR
J Bone Miner Res; 2009 Jul; 24(7):1147-9. PubMed ID: 19419311
[No Abstract] [Full Text] [Related]
2. [SDF-1/CXCR4 and multiple myeloma osteolytic bone lesions--review].
Bao L; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):442-6. PubMed ID: 18426683
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
[TBL] [Abstract][Full Text] [Related]
4. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
Chong BF; Mohan C
Expert Opin Ther Targets; 2009 Oct; 13(10):1147-53. PubMed ID: 19670960
[TBL] [Abstract][Full Text] [Related]
5. The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?
Katz BZ; Tavor S
Leuk Lymphoma; 2009 Jul; 50(7):1067-8. PubMed ID: 19557626
[No Abstract] [Full Text] [Related]
6. The SDF-1/CXCR4 axis is a novel driver of vascular development of the glomerulus.
Floege J; Smeets B; Moeller MJ
J Am Soc Nephrol; 2009 Aug; 20(8):1659-61. PubMed ID: 19608697
[No Abstract] [Full Text] [Related]
7. Expression of CXCL12 and CXCR4 in pT3-stage gastric cancer does not correlate with peritoneal metastasis.
Tsuboi K; Kodera Y; Nakanishi H; Ito S; Mochizuki Y; Nakayama G; Koike M; Fujiwara M; Yamamura Y; Nakao A
Oncol Rep; 2008 Nov; 20(5):1117-23. PubMed ID: 18949410
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype.
Beider K; Bitner H; Leiba M; Gutwein O; Koren-Michowitz M; Ostrovsky O; Abraham M; Wald H; Galun E; Peled A; Nagler A
Oncotarget; 2014 Nov; 5(22):11283-96. PubMed ID: 25526031
[TBL] [Abstract][Full Text] [Related]
9. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.
Menu E; Asosingh K; Indraccolo S; De Raeve H; Van Riet I; Van Valckenborgh E; Vande Broek I; Fujii N; Tamamura H; Van Camp B; Vanderkerken K
Haematologica; 2006 May; 91(5):605-12. PubMed ID: 16627256
[TBL] [Abstract][Full Text] [Related]
10. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
11. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss.
Diamond P; Labrinidis A; Martin SK; Farrugia AN; Gronthos S; To LB; Fujii N; O'Loughlin PD; Evdokiou A; Zannettino AC
J Bone Miner Res; 2009 Jul; 24(7):1150-61. PubMed ID: 19335218
[TBL] [Abstract][Full Text] [Related]
12. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis.
Wang J; Loberg R; Taichman RS
Cancer Metastasis Rev; 2006 Dec; 25(4):573-87. PubMed ID: 17165132
[TBL] [Abstract][Full Text] [Related]
13. Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer.
Sasaki K; Natsugoe S; Ishigami S; Matsumoto M; Okumura H; Setoyama T; Uchikado Y; Kita Y; Tamotsu K; Sakurai T; Owaki T; Aikou T
J Surg Oncol; 2008 Apr; 97(5):433-8. PubMed ID: 18176915
[TBL] [Abstract][Full Text] [Related]
14. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
[TBL] [Abstract][Full Text] [Related]
15. CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain.
Luo X; Wang X; Xia Z; Chung SK; Cheung CW
Rev Neurosci; 2016 Jan; 27(1):83-92. PubMed ID: 26353174
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4.
Gazitt Y; Akay C
Stem Cells; 2004; 22(1):65-73. PubMed ID: 14688392
[TBL] [Abstract][Full Text] [Related]
17. Characterization of cDNA and genomic sequences encoding a canine chemokine receptor, CXCR4 and its ligand CXCL12.
Tsuchida S; Kagi A; Takahashi T
Vet Immunol Immunopathol; 2007 Apr; 116(3-4):219-25. PubMed ID: 17316828
[TBL] [Abstract][Full Text] [Related]
18. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML
Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056
[TBL] [Abstract][Full Text] [Related]
19. [Constitutive NF-kappaB activation in myeloma cells: its underlying mechanism and functional significance].
Otsuyama K
Rinsho Ketsueki; 2009 Jun; 50(6):461-7. PubMed ID: 19571505
[No Abstract] [Full Text] [Related]
20. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity.
Trentin L; Miorin M; Facco M; Baesso I; Carraro S; Cabrelle A; Maschio N; Bortoli M; Binotto G; Piazza F; Adami F; Zambello R; Agostini C; Semenzato G
Br J Haematol; 2007 Sep; 138(5):594-602. PubMed ID: 17686053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
